Skip to content

Study · Non-randomized trial · n = 4 · 1996

4 results

Evaluation of growth hormone (GH) responses to pulsed GH-releasing hormone administration using the MTT-ESTA bioassay.

Dattani MT, Winrow AP, Tuil'Pakov A, Pringle PJ, Hindmarsh PC, Brook CG, Marshall NJ

European journal of endocrinology1 Jul 1996Cited by 3 (Europe PMC)

PMID8765979 (opens in a new tab)DOI10.1530/eje.0.1350087 (opens in a new tab)PepBankPUB-08765979
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In four healthy adult men given pulsed intravenous GHRH(1-29)-NH2, the GH responses varied between individuals.

    In plain wordsIn four healthy men given GHRH(1-29)-NH2, the growth hormone response differed from person to person.

    Peptide
    Sermorelin
    Outcome
    MixedVariability of GH responses between volunteers
    Study

    n = 4

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.1 and 1.0 micrograms/kg · intravenous · two pulses weekly over 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Responses in the four individuals were variable.
    1 context sentence
    Summary · context
    Two pulses of GHRH(1-29)-NH2 were administered intravenously to the four adult male volunteers (aged 24-37 years) on a weekly basis over a 4-week period.
  2. 02HumanNon-randomized trialActivity measurement

    In four healthy adult men, GH bioactivity rose more than GH immunoactivity after GHRH(1-29)-NH2, so the bioactivity/immunoactivity ratio increased progressively as half of the response peaks were approached.

    In plain wordsIn four healthy men, active growth hormone rose faster than the amount measured by standard assay as GHRH(1-29)-NH2 responses neared their peaks.

    Peptide
    Sermorelin
    Outcome
    IncreaseBioactivity/immunoactivity ratio of GH near response peaks
    Study

    n = 4

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.1 and 1.0 micrograms/kg · intravenous · two pulses weekly over 4 weeksAs given in this study (human).

    Source sentences

    Summary
    However, although the immuno- and bioactivities generally agreed well, there was a systematic and progressive increase in the bioactivity/immunoactivity (B/I) ratios as half of the response peaks were approached.
    1 context sentence
    Summary · context
    Two pulses of GHRH(1-29)-NH2 were administered intravenously to the four adult male volunteers (aged 24-37 years) on a weekly basis over a 4-week period.
  3. 03HumanNon-randomized trialActivity measurement

    In four healthy adult men, the GH bioactivity/immunoactivity ratio returned to values close to unity after the peak concentrations that followed GHRH(1-29)-NH2.

    In plain wordsIn four healthy men, the gap between active and measured growth hormone closed again after the peak that followed GHRH(1-29)-NH2.

    Peptide
    Sermorelin
    Outcome
    DecreaseBioactivity/immunoactivity ratio of GH after the peak
    Study

    n = 4

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.1 and 1.0 micrograms/kg · intravenous · two pulses weekly over 4 weeksAs given in this study (human).

    Source sentences

    Summary
    After these peak concentrations, the B/I ratios subsequently returned to values that were close to unity.
    1 context sentence
    Summary · context
    Two pulses of GHRH(1-29)-NH2 were administered intravenously to the four adult male volunteers (aged 24-37 years) on a weekly basis over a 4-week period.

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 04HumanNot a test of Sermorelin aloneNon-randomized trialOther

    In samples from the two volunteers with the largest responses to GHRH(1-29)-NH2, the enhanced GH bioactivity of the peak samples was labile after long-term storage at -20 degrees C.

    In plain wordsIn lab tests, the extra growth hormone activity in peak blood samples from two volunteers faded after long storage in a freezer.

    Peptide
    Sermorelin
    Outcome
    Not applicableStability of enhanced GH bioactivity in stored samples
    Study

    n = 2

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The enhanced bioactivity of the peak samples from the two volunteers in whom the largest magnitudes of response were observed was found to be labile after long-term storage at -20 degrees C.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.